Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
Harry L A JanssenJin-Lin HouAsselah TarikHenry L Y ChanFabien ZoulimYasuhito TanakaEwa JanczewskaRonald G NahassStefan BourgeoisMaria ButiPietro LamperticoOliver LenzThierry VerbinnenJoris VandenbosscheWillem TalloenRonald KalmeijerMaria BeumontMichael BiermerUmesh ShuklaPublished in: Gut (2023)
In patients with non-cirrhotic CHB, JNJ-56136379+NA showed pronounced reductions in HBV DNA and HBV RNA, limited HBsAg or HBeAg declines in patients who are NCT HBeAg positive, and was well tolerated, but no clear benefit with regards to efficacy of JNJ-56136379 over NA was observed.